Regeneron Pharmaceuticals, Inc. - Common Stock — Bilan (NASDAQ:REGN)

Afficher le graphique complet Full chart

Financials

Total de l'actif 17.16 B25.43 B29.21 B33.08 B37.76 B40.56 B Total du passif 6.14 B6.67 B6.55 B7.11 B8.41 B9.3 B Total des capitaux propres 11.03 B18.77 B22.66 B25.97 B29.35 B31.26 B Total du passif et des capitaux propres 17.16 B25.43 B29.21 B33.08 B37.76 B40.56 B Dette totale 1.98 B1.98 B1.98 B1.98 B1.98 B1.99 B Dette nette 1.98 B1.98 B1.98 B1.98 B1.98 B-6.62 B

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

REGN

Financials

Regeneron Pharmaceuticals, Inc. - Common Stock

Nouvelles

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Here's Why Regeneron (REGN) is a Strong Value Stock

L’EMA accepte la thérapie génique de Regeneron pour une perte auditive rare

These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP)

Regeneron annonce des résultats positifs pour un traitement de l’amylose

BAYRY's Kerendia Label Expansion Application Gets Priority Review

Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE)

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

Company News for May 19, 2026